Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Planetary Resources, Inc., the asteroid mining company, announced today that it has secured US$21.1 million in Series A funding. The capital will be used to deploy and operate Ceres, an advanced Earth observation business that features the first commercial infrared and hyperspectral sensor platform to better understand and manage humanity’s natural resources. The funding was led by Bryan Johnson and the OS FUND; and joined by Idea Bulb Ventures; Tencant; Vast Ventures; Grishin Robotics; Conversion Capital; The Seraph Group; Space Angels Network, a syndication of investors from Angel.co; and Larry Page. Earth observation will be another aspect of Planetary Resources’ operations in addition to prospecting and mining asteroids.
Conceived from the company’s vision for the exploration and utilization of asteroid resources, Ceres will leverage Planetary Resources’ Arkyd spacecraft to deliver affordable, on-demand Earth intelligence of our natural resources on any spot on the planet. While typical satellite imagery provides only a picture, Ceres will provide actionable data with higher spectral resolutions – going beyond what the human eye can see – by measuring thermographic properties and detecting the composition of materials on Earth’s surface. The midwave-infrared sensor is the first ever commercial capability from space to offer thermographic mapping and night-imaging, and the hyperspectral sensor includes an unprecedented 40 color bands in the visible to near-infrared spectrum.
To view the multimedia release go to:
http://www.multivu.com/players/English/7847251-planetary-resources-ceres/
Leviton today introduced a full line of residential Occupancy and Vacancy Sensors that combine state-of-the-art technology with a sleek new design to provide optimal management of lighting and motor loads. Available in either Automatic-ON (Occupancy) or Manual-ON (Vacancy) switching, these energy-saving sensors are available in models engineered to control current LED, CFL, fluorescent, incandescent, halogen or motor loads. Leviton Sensors help manage energy consumption and costs by ensuring that lights/loads will turn OFF automatically when a space is unoccupied and motion is no longer detected within the covered range.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57096-leviton-residential-motion-sensors-energy-efficiency-occupancy-manual
According to Congress’ “Don’t Let the Bed Bugs Bite” Act of 2009, bed bug populations have grown by 500 percent in the United States in recent years, primarily due to increased travel and antique merchandise. Bed bugs are creepy, crawly and hard to kill – an emotional topic that literally and figuratively keeps people up at night. Becoming educated on the bug, its habits, detecting, treating and preventing an infestation is an effective first step to control. Luckily, there is a solution: Ortho Home Defense Max BEDBUG Killer. Take back your bed and keep the critters from turning bedtime into bite time.
To view Multimedia News Release, go to http://www.multivu.com/players/English/47692-Ortho-Home-Defense-Max-BEDBUG-Killer/
Next time you get the feeling that the floor is falling out from beneath your feet, it might just be an ESP Detection Floor that comes to your aid. Developed in the Netherlands, the ESP Detection Floor system uses electronic flooring underlay panels to monitor rooms by detecting human movement.
The panels detect if someone has fallen over and automatically notify an emergency control center.. Of course, when it comes to flooring, aesthetic design is just as important as functionality. Which is why DOMOTEX 2014 will explore trends in flooring functionality and design. The rug designer Jürgen Dahlmanns and the internationally renowned architect Jürgen Mayer H. have given a preview of their contributions to DOMOTEX 2014.
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
